New bid rumors heat up Merck KGaA stock

Germany's Merck KGaA says that it expects to reap a €5 billion windfall from the sale of its generics unit, as new market rumors circulate over possible bidders. Merck's stock has been boosted by reports that executives have set a Monday deadline for non-binding bids. Teva, Mylan, Actavis and Ranbaxy have all been cited as active suitors. Bain, KKR and Warburg Pincus have been named among the financial groups that could make a bid as well.

- read the AFX report on the latest concerning the takeover talks

Related Articles:
Merck KGaA buying control of Serono. Report
Merck KGaA licenses Glenmark diabetes drug. Report